Black Rock Inc. Century Therapeutics, Inc. Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Century Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 1,498,181 shares of IPSC stock, worth $3.82 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,498,181

Previous 1,518,996 1.37%

Holding current value

$3.82 Million

Previous $5.04 Million 24.17%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$3.19 - $5.32 $66,399 - $110,735	-20,815 Reduced 1.37%	1,498,181 $6.26 Million
Q4 2023 Feb 13, 2024	SELL	$1.28 - $3.32 $97,405 - $252,645	-76,098 Reduced 4.77%	1,518,996 $5.04 Million
Q3 2023 Nov 13, 2023	SELL	$2.0 - $3.23 $40,160 - $64,858	-20,080 Reduced 1.24%	1,595,094 $3.19 Million
Q2 2023 Aug 11, 2023	BUY	$2.91 - $3.53 $592,839 - $719,149	203,725 Added 14.43%	1,615,174 $5.1 Million
Q1 2023 May 12, 2023	SELL	$3.4 - $5.11 $143,806 - $216,132	-42,296 Reduced 2.91%	1,411,449 $4.9 Million

Q4 2022 Feb 13, 2023	BUY	$4.84 - $11.58 $215,776 - $516,259	44,582 Added 3.16%	1,453,745 $7.46 Million
Q3 2022 Nov 14, 2022	BUY	$8.57 - $13.1 $882,521 - $1.35 Million	102,978 Added 7.88%	1,409,163 $13.9 Million
Q2 2022 Aug 12, 2022	BUY	$7.96 - $12.43 $2.21 Million - $3.45 Million	277,928 Added 27.03%	1,306,185 $11 Million
Q1 2022 May 12, 2022	BUY	$11.62 - $15.92 $2.33 Million - $3.2 Million	200,834 Added 24.27%	1,028,257 $12.9 Million
Q4 2021 Feb 10, 2022	BUY	$13.93 - $23.62 $2.49 Million - $4.22 Million	178,767 Added 27.56%	827,423 $13.1 Million
Q3 2021 Nov 09, 2021	BUY	$20.8 - $31.93 $13.5 Million - $20.7 Million	648,656 New	648,656 $16.3 Million

Others Institutions Holding IPSC

# of Institutions

Shares Held

19.7M

Call Options Held

10.6K

Put Options Held

300

View Full List

About Century Therapeutics, Inc.

Ticker IPSC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,881,800
Market Cap $150M
Description
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...

More about IPSC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account